Medtronic does not provide sales figures specifically for the DBS device, Resman said. Medtronic shares were down 0.1 percent at $44.71 in late morning trading on the New York Stock Exchange. The ...

Medtronic, battered by a high number of serious medical device recalls in recent years, says it is toughening its internal assessments for acquiring new products. The company, operationally based ...

Medtronic is currently the only company selling FDA-approved, rechargable DBS devices in the country, a distinction that has helped second quarter neurostimulation sales jump 11 percent to $394 ...

--Medtronic plc today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation therapy at the Samsung Developers Conference in San Jose, Calif. Food and ...

Two Medtronic deep brain stimulation device-implants, in combination with drugs, helped improve symptoms in patients with early-stage Parkinson's disease, according to a new study. ...

A deep brain stimulation device used to treat conditions like Parkinson's disease was classified Thursday by the U.S. Food and Drug Administration as a Class I recall — meaning the FDA believes ...

Medtronic plc MDT recently received the FDA’s approval for the Percept RC Deep Brain Stimulation ... the global DBS devices market was valued at $1.18 billion in 2022 and is expected to witness ...

A new deep brain stimulation system by Medtronic can sense and record brain activity at the same time it delivers therapy to treat Parkinson's symptoms, essential tremors and epilepsy. The data ...

Fridley-based Medtronic announced that its new treatment targeting epilepsy has received regulatory approval in the European Union. The company said that the so-called CE Mark will allow its deep ...

Medtronic has published preliminary data from a study of its adaptive deep brain stimulation (aDBS) device, Percept PC neurostimulator, in patients living with Parkinson’s disease. The adaptive ...